ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Largely Unaffected By NIH Translational Research Center

February 11, 2011

DeVita Asks Panel For Help On Filling Vacancies, Object To “Effort To Get Us Back To 1970 Level”

November 21, 1980

NCCS Networker Volume 2 Issue 1, Winter 1988

January 13, 1988

Rep. Bliley Challenges FDA On Failure To Approve Oral Colon Cancer Drug UFT.

April 21, 2000

Scientists, advocates voice objections to von Eschenbach’s conflicts, 2015.

November 23, 2005

President’s Surgery Stirs Interest In Colon Cancer Exams

July 26, 1985